Objective To investigate the efficacy of Aflibercept combined with Ranibizumab in the treatment of dia-betic macular edema.Methods Clinical data of 90 patients with diabetic macular edema who were admitted to the Sixth Affiliated Hospital of Guangzhou Medical University from September 2021 to September 2022 were retrospective selected.According to the difference of medication,they were divided into two groups.The control group(n=45,all unilateral eye lesions)received Ranibizumab continued treatment.The observation group(n=45,all with unilateral ocular lesions)received Ranibizumab combined with Aflibercept.Baseline visual acuity,intraocular pressure,retinal thickness were compared after treatment and incidence of adverse reaction.Results There was no statistically signifi-cant difference between the observation group and the control group in visual acuity,macular central thickness and in-traocular pressure before treatment(all P>0.05).After treatment,the visual acuity ratio in the observation group was significantly higher than that in the control group.The macular central thickness and intraocular pressure in the obser-vation group were significantly lower than those in the control group,and the differences were statistically significant(both P<0.05).There was no statistically significant difference between two groups in incidence of adverse reaction(P>0.05).Conclusion For Diabetic macular edema patients with poor treatment effect of Ranibizumab,the combination of Aflibercept will improve the visual acuity of patients and improve the retinal structure,the alternative therapy of Af-libercept is safe,effective.
NETL
NSTL
万方数据
